Ketamine nasal spray shows promise against treatment-resistant depression

The trial is the first to compare esketamine against another commonly used add-on drug, authors say.
HealthDay News

A nasal spray containing a ketamine derivative appears to beat one of the standard drugs for patients with treatment-resistant depression, a study has found.

The trial, of nearly 700 people with treatment-resistant depression, found that esketamine nasal spray was more effective at achieving remission than a standard oral drug quetiapine (Seroquel).